Cargando…
OR30-01 Real-World Minimed™ 670G System Use and Glycemic Outcomes of Pediatric and Adult Individuals Living with Type 1 Diabetes (T1D) in the United States
Introduction: The MiniMed™ 670G system was FDA-approved in 2016 for adults and adolescents ≥14yrs, and in 2018 for children ages 7-13yrs with T1D. Since then, use of the system has grown to over 180,000 people in the U.S. The glycemic control benefits of real-world MiniMed™ 670G system Auto Mode use...
Autores principales: | Vigersky, Robert Alan, Stone, Michael, Agrawal, Pratik, Zhong, Alex, Velado, Kevin, Cordero, Toni, Shin, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207810/ http://dx.doi.org/10.1210/jendso/bvaa046.1708 |
Ejemplares similares
-
An Analysis of Medtronic Minimed 670g Insulin Pump Use in Clinical Practice and the Impact on Glycemic Control, Quality of Life, and Compliance
por: Horowitz, Maxwell E, et al.
Publicado: (2021) -
MON-670 An Overlooked Cause of Diabetic Pain
por: Arzeno, Luis Enrique, et al.
Publicado: (2020) -
SAT-670 The Perfect Storm for Diabetic Ketoacidosis
por: Abushamat, Layla A, et al.
Publicado: (2020) -
The Effectiveness of Virtual Training on the MiniMed™ 670G System in People with Type 1 Diabetes During the COVID-19 Pandemic
por: Vigersky, Robert A., et al.
Publicado: (2021) -
SAT-126 The Relationship of Continuous Glucose Monitoring (CGM)-Derived Time-in-Range (TIR) to Hemoglobin A1c (HbA1c)
por: Vigersky, Robert, et al.
Publicado: (2019)